- Home
- WOLF vs VOR Comparison
WOLF vs VOR Comparison
Compare WOLF & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WOLF
- VOR
- Stock Information
- Founded
- WOLF 1987
- VOR 2015
- Country
- WOLF United States
- VOR United States
- Employees
- WOLF N/A
- VOR N/A
- Industry
- WOLF Semiconductors
- VOR Biotechnology: Pharmaceutical Preparations
- Sector
- WOLF Technology
- VOR Health Care
- Exchange
- WOLF Nasdaq
- VOR Nasdaq
- Market Cap
- WOLF 200.8M
- VOR 202.4M
- IPO Year
- WOLF 1993
- VOR 2021
- Fundamental
- Price
- WOLF $1.55
- VOR $2.21
- Analyst Decision
- WOLF Hold
- VOR Buy
- Analyst Count
- WOLF 13
- VOR 7
- Target Price
- WOLF $10.67
- VOR $3.77
- AVG Volume (30 Days)
- WOLF 154.0M
- VOR 48.9M
- Earning Date
- WOLF 08-20-2025
- VOR 08-07-2025
- Dividend Yield
- WOLF N/A
- VOR N/A
- EPS Growth
- WOLF N/A
- VOR N/A
- EPS
- WOLF N/A
- VOR N/A
- Revenue
- WOLF $761,300,000.00
- VOR N/A
- Revenue This Year
- WOLF N/A
- VOR N/A
- Revenue Next Year
- WOLF $14.42
- VOR N/A
- P/E Ratio
- WOLF N/A
- VOR N/A
- Revenue Growth
- WOLF N/A
- VOR N/A
- 52 Week Low
- WOLF $0.39
- VOR $0.13
- 52 Week High
- WOLF $3.33
- VOR $3.29
- Technical
- Relative Strength Index (RSI)
- WOLF 49.56
- VOR 68.95
- Support Level
- WOLF $1.38
- VOR $1.92
- Resistance Level
- WOLF $1.77
- VOR $2.65
- Average True Range (ATR)
- WOLF 0.44
- VOR 0.54
- MACD
- WOLF 0.06
- VOR 0.01
- Stochastic Oscillator
- WOLF 35.38
- VOR 58.49
About WOLF Wolfspeed Inc.
Wolfspeed Inc is involved in the manufacturing of wide bandgap semiconductors. It is focused on silicon carbide and gallium nitride materials and devices for power and radio-frequency (RF) applications. The company serves applications such as transportation, power supplies, inverters, and wireless systems. Geographically, it derives a majority of its revenue from Europe and the rest from the United States, China, Hong Kong, Asia Pacific, and other regions.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.